Scinai Immunotherapeutics Ltd. (SCNI) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Jerusalem, 以色列. 现任CEO为 Amir Reichman.
SCNI 拥有 IPO日期为 2015-05-11, 31 名全职员工, 在 NASDAQ Capital Marke, 市值为 $802.37K.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
